BerGenBio Adds Another Brick To AXL Inhibitor Bemcentinib’s AML Potential

As the most advanced AXL inhibitor product in the global pipeline, BerGenBio’s bemcentinib has continued to show encouraging data in AML, following on from monotherapy trials last year.

Bricklayer
• Source: Shutterstock

Norwegian biotech BerGenBio ASA’s first-in-class AXL inhibitor has met its first efficacy endpoints in a Phase II clinical trial evaluating bemcentinib in combination with low-dose cytarabine (LDAC) as a potential new treatment regimen for acute myeloid leukaemia (AML) patients unable to tolerate intensive therapy.

Top-line data from the pre-specified efficacy endpoint in this trial requires at least three patients out of the first 14...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anticancer

More from Therapeutic Category